Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Other: Pulmonary rehabilitation
- Registration Number
- NCT03244137
- Lead Sponsor
- ADIR Association
- Brief Summary
Chronic obstructive pulmonary disease is a leading cause of mortality worldwide.
It is a systemic disease which includes pulmonary, cardiac, muscular, digestive and cognitive impairments.
Pulmonary rehabilitation is a symptomatic treatment to reduce dyspnea and functional incapacity. However, it effects on cognitive dysfunction are not well known.
The aim of this study is to assess the effects of a comprehensive pulmonary rehabilitation program on cognitive dysfunction in patients with severe to very severe chronic obstructive pulmonary disease using the Montreal Cognitive Assessment tool.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 56
- Age > 18years;
- Chronic obstructive pulmonary disease stade III to IV;
- Referred for pulmonary rehabilitation.
Non Inclusion Criteria:
- Pregnancy or likely to be;
- History of psychiatric, neuro-vascular, cognitive disease or cranial trauma;
- Active alcoholism;
- Guardianship;
- Hospitalisation for acute exacerbation of chronic obstructive pulmonary disease in the previous 4 weeks;
- Interruption of the pulmonary rehabilitation program > 15 days;
- Disruption of the training before the 18th session;
- Less than 18 sessions in four month.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Pulmonary rehabilitation Pulmonary rehabilitation The whole population will benefit from a comprehensive pulmonary rehabilitation program, including aerobic training, superior and inferior limb strength training, self-management and add-on to pulmonary rehabilitation as needed (i.e : electrical muscle stimulation, inspiratory muscle training, non-invasive ventilation, high flow nasal canula).
- Primary Outcome Measures
Name Time Method Baseline cognitive function Cognitive function is assessed at the beginning of the rehabilitation program : day 0 Cognitive function is assessed with the Montreal Cognitive Assessement tool
Cognitive function : follow up Cognitive function is assessed 3 month after rehabilitation : day 150 Cognitive function is assessed with the Montreal Cognitive Assessement tool
Cognitive function after pulmonary rehabilitation Cognitive function is assessed at the end of the rehabilitation program : day 60 Cognitive function is assessed with the Montreal Cognitive Assessement tool
Change in cognitive function from baseline to the end of pulmonary rehabilitation Change in cognitive function from baseline to the end of pulmonary rehabilitation is assessed with end of pulmonary rehabilitation minus baseline values (day 60 - day 0) Cognitive function is assessed with the Montreal Cognitive Assessement tool
Change in cognitive function from the end of pulmonary rehabilitation to 3 month of follow up Change in cognitive function from the end of pulmonary rehabilitation to 3 month of follow up is assessed with the 3 month of follow minus the end of pulmonary rehabilitation values (day 150 - day 60) Cognitive function is assessed with the Montreal Cognitive Assessement tool
- Secondary Outcome Measures
Name Time Method Functional capacity (six-minute stepper test) : baseline Functional capacity is assessed at the beginning of the rehabilitation program : day 0 Functional capacity is assessed with the six-minute stepper test
Functional capacity (six-minute stepper test) : end of pulmonary rehabilitation Functional capacity is assessed at the end of the rehabilitation program : day 60 Functional capacity is assessed with the six-minute stepper test
Anxiety and depression : end of pulmonary rehabilitation Anxiety and depression are assessed at the end of the rehabilitation program : day 60 Anxiety and depression are assessed with the Hospital Anxiety and Depression scale (HAD).
Quality of life : end of pulmonary rehabilitation Quality of life is assessed at the end of the rehabilitation program : day 60 Quality of life is assessed using the Saint Georges Respiratory Questionnaire
Quality of life : follow-up Quality of life is assessed 3 month after the end of the rehabilitation program : day 150 Quality of life is assessed using the Saint Georges Respiratory Questionnaire
Anxiety and depression : baseline Anxiety and depression are assessed at the beginning of the rehabilitation program : day 0 Anxiety and depression are assessed with the Hospital Anxiety and Depression scale (HAD).
Anxiety and depression : follow up Anxiety and depression are assesses 3 month after the end of pulmonary rehabilitation program : day 150 Anxiety and depression are assessed with the Hospital Anxiety and Depression scale (HAD).
Quality of life : baseline Quality of life is assessed at the beginning of the rehabilitation program : day 0 Quality of life is assessed using the Saint Georges Respiratory Questionnaire
Functional capacity (six-minute walk test) : baseline Functional capacity is assessed at the beginning of the rehabilitation program : day 0 Functional capacity is assessed with the six-minute walk test
Relation between the cognitive function and the respiratory function (forced expiratory volume in 1 second) The relation is assessed between baseline demographic data at day 0 Cognitive function is assessed with the Montreal Cognitive Assessement tool and respiratory function is assessed with spirometric evaluation
Adherence Adherence is assessed at the end of the rehabilitation program : day 60 Adherence to the pulmonary rehabilitation program is assessed by the following equation : number of session performed divided by the number of scheduled sessions
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (2)
Bonnevie
🇫🇷Bois-Guillaume, France
Médrinal
🇫🇷Le Havre, France
Bonnevie🇫🇷Bois-Guillaume, France